Info

Aurigene's business model comprises Early Stage Partnerships, Licensing and Co-development, and Specialized services in the areas of Crystallography, Peptide and Small molecule synthesis and non-GMP scale-up, and ADME assays. Aurigene's business model involves early stage Discovery collaborations, starting with either a Partner's Target or Hits. Typical collaborations end with the delivery of an IND-ready candidate by Aurigene. Aurigene is also identifying and building a portfolio of product opportunities for licensing. These are typically Aurigene-funded Discovery programs, and also include a portfolio of Discovery Programs discontinued by Aurigene's partners for strategic reasons. These projects are available for Licensing and co-development. Aurigene has been a very flexible partner, tailoring the Business Approach to suit specific collaborator needs. Increasing scope and scale of relationships with its partners over the years has validated Aurigene's key value propositions of World-class Science, cost-effective innovation, speed to Discovery (20-30 months from Target to IND) and Flexible business Model. Aurigene is an independent subsidiary of Dr. Reddy's Laboratories Limited (DRL). DRL is listed both on the New York Stock Exchange (NYSE) and on the Bombay Stock Exchange (BSE) with significant operations in the USA and Europe. © 2008, Aurigene Discovery Technologies Limited.